Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160 | Completed Phase 2 Results

• 2 other identifiers: 03028403-C-0284
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is three-fold: 1) to examine the ability of the experimental drug tariquidar to improve chemotherapy results by blocking a protein (P-glycoprotein) on some cancer cells that acts to pump out cancer drugs; 2) examine how tariquidar interacts with the cancer drug docetaxel; and 3) evaluate the effectiveness of combination treatment with tariquidar and docetaxel in treating patients with lung, ovarian, or cervical cancer. Patients 18 years of age and older with recurrent or metastatic (spreading) lung, cervical, or ovarian cancer who cannot benefit from any standard treatment may be eligible for this study. Candidates will be screened with a medical history and physical examination; review of pathology slides; blood and urine tests; imaging tests, including computed tomography (CT) or magnetic resonance imaging (MRI) scans; chest x-ray, electrocardiogram (EKG); and possibly echocardiogram. Participants will undergo the following tests and procedures: Blood draw. Blood is drawn before treatment begins to establish baseline levels for future blood tests. Blood counts are done twice weekly after chemotherapy begins. Central venous catheter placement. A plastic tube is put into a major vein in the chest. It is used to give the study drugs or other medications, including antibiotics and blood transfusions, if needed, and to withdraw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room. It can stay in the body for months or be removed after each treatment is completed. Chemotherapy. Treatment cycles are 21 days. Both drugs are given on day 1 of each cycle. First, tariquidar is given as a 30-minute infusion. One hour after the tariquidar infusion, docetaxel is infused over 1 hour. (For the first cycle only, docetaxel is given in divided doses one week apart and tariquidar is administered on either day 1 or day 8. The order of tariquidar administration is randomized to generate optimal pharmacokinetic data. Patients will be hospitalized for several days during this cycle to gather research data). The tariquidar dose remains the same throughout the study. Docetaxel may be increased or decreased from cycle to cycle, based on side effects.

Conditions

Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms; Renal Neoplasms

Keywords

Pharmacokinetics; Pharmacodynamics; Multidrug Resistance Reversal; Molecular Target; P-Glycoprotein Inhibition; Lung Cancer; Ovarian Cancer; Cervical Cancer; Renal Cancer

Outcome Measures

Primary Outcomes (4)

• Geometric Mean of Maximum Concentration of the Drug (Cmax)

  In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.

  24 hours

• The Number of Participants With Adverse Events.

  Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

  4 yrs 8-11 months

• Geometric Mean of Area Under Curve (AUC0)-24

  24 hours

• Clinical Response Rate

  Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>/- 20 mm with conventional techniques (CT, MRI, xray) or as \>/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter \<20 mm with conventional techniques or \<10 mm using spiral CT.

  4 years, 8-11 months

Secondary Outcomes (2)

• Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar

  3 - 24 hours

• Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue

  3-24 hours

Study Arms (2)

Pts who received docetaxel on day 1, 8, & tariquidar day 8,22

EXPERIMENTAL

Patients receive 40 mg/m\^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m\^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.

Drug: docetaxel; Drug: tariquidar; Other: 99mTc-sestamibi imaging

Pts who received docetaxel on days 1, 8, & tariquidar day 1,22

EXPERIMENTAL

Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.

Drug: docetaxel; Drug: tariquidar; Other: 99mTc-sestamibi imaging

Interventions

docetaxel DRUG

Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.

Also known as: Taxotere

Pts who received docetaxel on day 1, 8, & tariquidar day 8,22; Pts who received docetaxel on days 1, 8, & tariquidar day 1,22

tariquidar DRUG

Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.

Also known as: XR9576

Pts who received docetaxel on day 1, 8, & tariquidar day 8,22; Pts who received docetaxel on days 1, 8, & tariquidar day 1,22

99mTc-sestamibi imaging OTHER

Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.

Also known as: Cardiolite

Pts who received docetaxel on day 1, 8, & tariquidar day 8,22; Pts who received docetaxel on days 1, 8, & tariquidar day 1,22

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must fulfill all of the following criteria to be eligible for study admission:
• Age greater than or equal to 18 years.
• Histologic or cytologic confirmation of lung, cervical, or ovarian cancer, following at least one standard treatment regimen, and for which there is no known standard therapy capable of extending life expectancy. Female patients with primary papillary carcinoma of the peritoneum and fallopian tube cancers will be included in the latter group, as the disease entities are closely associated with epithelial ovarian carcinoma, can be difficult to distinguish, have a similar epithelial origin, and are treated in an identical manner.
• Histologic or cytologic confirmation of renal cell carcinoma (clear cell, type 1 and type II papillary chromophobe, collecting duct and medullary). Patients should have received either sunitinib or sorafenib, unless deemed ineligible for treatment with either agent. In addition,patient should either: (a) have received IL-2; (b) have been evaluated for therapy with Interleukin-2 (IL- 2) and deemed to be ineligible; or (c) have been evaluated for therapy with IL2 and refused treatment.
• Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2
• Life expectancy of 3 months or greater.
• Suitable candidate for receiving planned therapy as evidenced by screening laboratory assessments hematologic, renal hepatic, and metabolic functions, platelet count greater than or equal to 90,000/mL, absolute granulocyte count(AGC) greater than or equal to 1,500/mL, serum creatinine greater than or equal to 1,500/mL, serum creatine less than or equal to 1.5 mg/dl )or if greater than 1.5 a measured 24 hour creatinine clearance greater than or equal to 50 mL/min) and serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x normal limit (NL) and bilirubin less than or equal to 1.5 x NL (in patients with clinical evidence of Gilbert's disease,less than or equal to 3 x NL).
• Patients must be greater than or equal to 4 weeks prior radiation or chemotherapy, greater than 2 weeks from hormonal therapy; greater than 4 weeks from prior experimental therapy; greater than 6 weeks from mitomycin C; and greater than 8 weeks from prior UCN01 treatment.
• No serious intercurrent medical illness.
• Measurable disease by radiographic means or physical examination. For ovarian cancer, assessable disease by cancer antigen 125 (CA125) measurement is allowed.
• Willingness to sign a written consent form, and to comply with the protocol.

You may not qualify if:

• The following patient populations are not eligible for this study.
• Pregnant or nursing women are not eligible; women of childbearing age must agree to use an effective method of contraception. Pregnant women are not eligible because of teratogenic effects of chemotherapy.
• The presence of a second malignancy that has not received primary treatment or would complicate the primary objective of this study.
• Patients who are poor medical risk because of active, uncontrolled infection or other nonmalignant systemic disease.
• Human immunodeficiency virus (HIV) seropositive patients. Patients infected with the HIV virus will be excluded from this trial because the effect of the combination of tariquidar and docetaxel on HIV replication and/or the immune system is unknown and potentially harmful.
• Patients receiving agents which have major interactions with the cytochrome P450 3A4 (CYP3A4)drug metabolizing system and which cannot be discontinued may not be included in the trial.
• Untreated brain metastases (or local treatment of brain metastases within the last 6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause of neurologic toxicities.

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (1)

National Institutes of Health

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103-16. doi: 10.1002/jcp.1040830114. No abstract available.

  PMID: 4855907 BACKGROUND

• Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 1985 Mar;11(2):117-26. doi: 10.1007/BF01534700.

  PMID: 3856953 BACKGROUND

• Beck WT, Cirtain MC, Lefko JL. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol. 1983 Nov;24(3):485-92.

  PMID: 6579344 BACKGROUND

• Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2011 Feb 1;17(3):569-80. doi: 10.1158/1078-0432.CCR-10-1725. Epub 2010 Nov 16.

  PMID: 21081657 RESULT

Related Links

• Medline Plus
• Drug Information
• U.S. FDA Resources

MeSH Terms

Conditions

Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms; Kidney Neoplasms

Interventions

Docetaxel; tariquidar; Technetium Tc 99m Sestamibi

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Uterine Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Urologic Neoplasms; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Nitriles; Organotechnetium Compounds; Organometallic Compounds

Results Point of Contact

• Title: Susan E. Bates, M.D.
• Organization: National Cancer Institute, National Institutes of Health

BatesS@mail.nih.gov

301-402-1357

Study Officials

• Susan E Bates, M.D.

  NCI, NIH

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH

Study Record Dates

• First Submitted: September 15, 2003
• First Posted: September 16, 2003
• Study Start: September 1, 2003
• Primary Completion: December 1, 2009
• Study Completion: December 1, 2009
• Last Updated: October 12, 2012
• Results First Posted: October 12, 2012

Record last verified: 2012-09

Locations

US (1)